Johnson & Johnson

Adjusted profit was $2.42 a share, surpassing Wall Street's average estimate of $2.19. Pharmaceutical revenue rose almost 5 per cent, exceeding expectations by more than $400 million

J&J recently garnered support from more than 75 per cent of baby powder claimants for an out-of-court deal that includes claims that the talc-based version caused ovarian and other gynecological cance

The increase would boost the size of the settlement to more than $9 billion paid over 25 years

Separately, the company said in May it has resolved 95% of claims its baby powder was tainted with asbestos and caused mesothelioma, a type of cancer that forms in tissues around the heart and lungs

Adjusted earnings for the quarter were $2.82 a share, the New Brunswick, New Jersey-based company said Wednesday in a statement, beating analysts' average estimate by 11 cents

A subsidiary of Johnson and Johnson is now proposing paying approximately USD 6.48 billion over 25 years as part of a settlement to cover allegations that its baby powder containing talc caused ovarian cancer. The lawsuits filed against JandJ had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs. JandJ said that the reorganization plan for the subsidiary that was being announced on Wednesday was significantly different from the previous reorganization that was announced. Those differences include a three-month solicitation period during which ovarian claimants can vote for or against the plan. This is something that was denied in prior bankruptcy cases, the company said. And if 75 per cent of claimants vote in favor of the plan, a subsidiary may file a prepackaged Chapter 11 bankruptcy to secure its confirmation. The remaining pending personal injury lawsuits that rel

Under the deal, J&J would pay $335 per share in cash for the medical device maker. The offer price implies a 4.7% premium to Shockwave's last close of $319.99 on Thursday

The drug, nipocalimab, significantly reduced symptoms of generalized myasthenia gravis (gMG) in a late-stage study, and in a mid-stage study helped reduce Sjogren's disease severity, J&J said

BENGALURU (Reuters) - Indian consumer goods maker Procter & Gamble Hygiene and Health Care reported higher second-quarter net profit on Wednesday, as lower costs countered a small drop in sales.

The company filed a request last month with the Texas secretary of state's office to relocate its LTL Management unit to Austin and rename it ahead of a Chapter 11 filing in the state

The pharma and medical devices giant will soon lose its exclusivity with psoriasis treatment Stelara, which accounted for a fifth of its drug sales in the third quarter

Attorneys for some plaintiffs opposed the idea of a return to bankruptcy court

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading

Jurors in state court in state court in Oakland concluded Tuesday that J&J's baby powder helped cause Anthony Hernandez Valadez's mesothelioma, a specific type of cancer linked to asbestos exposure

A federal judge ordered a new round of settlement talks between Johnson & Johnson and lawyers who spurned the company's offer to pay $8.9 billion to end tens of thousands of cancer claims

J&J has an $8.9 billion settlement agreement with the "vast majority" of the law firms representing talc claimants, said the company's head of litigation

The healthcare products maker is trying for the second time to get itself out of a jam as cheaply as possible, using the Chapter 11 filing of LTL Management

LTL has the backing of 60,000 victims, or about two thirds of all claimants, lawyer Gregory M. Gordon said in federal court on Tuesday

Indian Patent Office's decision on J&J's bedaquiline came on the eve of World Tuberculosis Day, marked on March 24 every year, to raise public awareness & to boost efforts to end the TB epidemic

Shares of the drugmaker were up nearly 1% at $170.28 in trading before the bell